222 related articles for article (PubMed ID: 2579648)
1. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell.
Saito M; Yu RK; Cheung NK
Biochem Biophys Res Commun; 1985 Feb; 127(1):1-7. PubMed ID: 2579648
[TBL] [Abstract][Full Text] [Related]
2. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies.
Ye JN; Cheung NK
Int J Cancer; 1992 Jan; 50(2):197-201. PubMed ID: 1730513
[TBL] [Abstract][Full Text] [Related]
3. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
Cheung NK; Canete A; Cheung IY; Ye JN; Liu C
Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
5. Different fine binding specificities of monoclonal antibodies to disialosylganglioside GD2.
Tai T; Kawashima I; Tada N; Dairiki K
J Biochem; 1988 Apr; 103(4):682-7. PubMed ID: 3170507
[TBL] [Abstract][Full Text] [Related]
6. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins.
Cheresh DA; Pierschbacher MD; Herzig MA; Mujoo K
J Cell Biol; 1986 Mar; 102(3):688-96. PubMed ID: 3005335
[TBL] [Abstract][Full Text] [Related]
7. Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2).
Moutel S; Birkle S; Laurence V; Michon J; Fridman WH; Aubry J; Teillaud JL
Hybridoma; 1997 Aug; 16(4):335-46. PubMed ID: 9309424
[TBL] [Abstract][Full Text] [Related]
8. New anti-GD2 monoclonal antibodies produced from gamma-interferon-treated neuroblastoma cells.
Gross N; Beck D; Portoukalian J; Favre S; Carrel S
Int J Cancer; 1989 Apr; 43(4):665-71. PubMed ID: 2467885
[TBL] [Abstract][Full Text] [Related]
9. Different reactivities of monoclonal antibodies to ganglioside lactones.
Tai T; Kawashima I; Tada N; Ikegami S
Biochim Biophys Acta; 1988 Jan; 958(1):134-8. PubMed ID: 3334863
[TBL] [Abstract][Full Text] [Related]
10. Characterization of human IgG1 monoclonal antibody against gangliosides expressed on tumor cells.
Mukerjee S; Nasoff M; McKnight M; Glassy M
Hybridoma; 1998 Apr; 17(2):133-42. PubMed ID: 9627053
[TBL] [Abstract][Full Text] [Related]
11. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
[TBL] [Abstract][Full Text] [Related]
12. Binding of monoclonal antibody A2B5 to gangliosides.
Kundu SK; Pleatman MA; Redwine WA; Boyd AE; Marcus DM
Biochem Biophys Res Commun; 1983 Nov; 116(3):836-42. PubMed ID: 6651849
[TBL] [Abstract][Full Text] [Related]
13. Production of monoclonal antibodies specific for ganglioside GD3.
Watarai S; Onuma M; Yasuda T
J Biochem; 1991 Dec; 110(6):889-95. PubMed ID: 1724444
[TBL] [Abstract][Full Text] [Related]
14. Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.
Zhao Q; Ahmed M; Guo HF; Cheung IY; Cheung NK
J Biol Chem; 2015 May; 290(21):13017-27. PubMed ID: 25851904
[TBL] [Abstract][Full Text] [Related]
15. Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas.
Longee DC; Wikstrand CJ; Månsson JE; He X; Fuller GN; Bigner SH; Fredman P; Svennerholm L; Bigner DD
Acta Neuropathol; 1991; 82(1):45-54. PubMed ID: 1659106
[TBL] [Abstract][Full Text] [Related]
16. Shedding of GD2 ganglioside by human neuroblastoma.
Ladisch S; Wu ZL; Feig S; Ulsh L; Schwartz E; Floutsis G; Wiley F; Lenarsky C; Seeger R
Int J Cancer; 1987 Jan; 39(1):73-6. PubMed ID: 3539825
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.
Honsik CJ; Jung G; Reisfeld RA
Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7893-7. PubMed ID: 3094017
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
[TBL] [Abstract][Full Text] [Related]
20. Distribution of disialoganglioside GD2-antigen and binding of anti-GD2 antibodies on spheroids of neuroblastoma cell line.
Heiss P; Bermatz S; Wehnes H; Heinzmann U; Senekowitsch-Schmidtke R
Anticancer Res; 1997; 17(4B):3145-7. PubMed ID: 9329622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
